Lytix Biopharma AS (LYTIX) - Total Liabilities

Latest as of December 2025: Nkr19.77 Million NOK ≈ $2.08 Million USD

Based on the latest financial reports, Lytix Biopharma AS (LYTIX) has total liabilities worth Nkr19.77 Million NOK (≈ $2.08 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Lytix Biopharma AS to evaluate the company's liquid asset resilience ratio.

Lytix Biopharma AS - Total Liabilities Trend (2017–2025)

This chart illustrates how Lytix Biopharma AS's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Lytix Biopharma AS total assets.

Lytix Biopharma AS Competitors by Total Liabilities

The table below lists competitors of Lytix Biopharma AS ranked by their total liabilities.

Company	Country	Total Liabilities
SUI Group Holdings Limited NASDAQ:SUIG	USA	$14.11 Million
Maan Aluminium Limited NSE:MAANALU	India	Rs1.18 Billion
SLP Resources Bhd KLSE:7248	Malaysia	RM19.80 Million
Seco/Warwick SA WAR:SWG	Poland	zł426.07 Million
Emkay Global Financial Services Limited NSE:EMKAY	India	Rs15.74 Billion
Case Group AB ST:CASE	Sweden	Skr51.81 Million
SM Culture & Contents Co. Ltd KQ:048550	Korea	₩134.83 Billion
Groupe LDLC SA PA:ALLDL	France	€164.91 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Lytix Biopharma AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Lytix Biopharma AS to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	0.57	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.32	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Lytix Biopharma AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Lytix Biopharma AS (2017–2025)

The table below shows the annual total liabilities of Lytix Biopharma AS from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	Nkr19.77 Million ≈ $2.08 Million	-48.83%
2024-12-31	Nkr38.64 Million ≈ $4.07 Million	+207.77%
2023-12-31	Nkr12.55 Million ≈ $1.32 Million	-25.67%
2022-12-31	Nkr16.89 Million ≈ $1.78 Million	+26.64%
2021-12-31	Nkr13.34 Million ≈ $1.40 Million	+4.79%
2020-12-31	Nkr12.73 Million ≈ $1.34 Million	+230.25%
2019-12-31	Nkr3.85 Million ≈ $405.55K	-78.41%
2018-12-31	Nkr17.85 Million ≈ $1.88 Million	-49.44%
2017-12-31	Nkr35.30 Million ≈ $3.71 Million	--

About Lytix Biopharma AS

OL:LYTIX Norway Biotechnology

Market Cap

$68.78 Million

Nkr653.65 Million NOK

Market Cap Rank

#20759 Global

#186 in Norway

Share Price

Nkr8.50

Change (1 day)

+1.43%

52-Week Range

Nkr6.90 - Nkr11.50

All Time High

Nkr18.60